

Steven R Alberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5188911/publications.pdf>

Version: 2024-02-01

75
papers

3,773
citations

159585

30
h-index

128289

60
g-index

75
all docs

75
docs citations

75
times ranked

5488
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	7.4	412
2	Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 E6201: A Trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3778-3785.	1.6	382
3	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	1.3	273
4	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3664-3672.	1.6	233
5	Prognostic Value of <i>BRAF</i> and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	6.3	201
6	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	140
7	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq1 1 0.784314 rgBT /Overlock 136	6.3	136
8	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i> "Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). <i>Clinical Cancer Research</i> , 2014, 20, 3033-3043.	7.0	129
9	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 843-853.	1.6	128
10	Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma. <i>Cancer</i> , 2005, 103, 111-118.	4.1	120
11	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	7.1	104
12	Racial Differences in <i>BRAF</i> / <i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv186.	6.3	98
13	Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. <i>Mayo Clinic Proceedings</i> , 2016, 91, 61-70.	3.0	85
14	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	1.6	84
15	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. <i>JAMA Oncology</i> , 2017, 3, 472.	7.1	82
16	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 5294-5304.	7.0	70
17	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	62
18	MIR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. <i>Scientific Reports</i> , 2017, 7, 43393.	3.3	61

#	ARTICLE	IF	CITATIONS
19	Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. <i>Cancer</i> , 1996, 78, 764-772.	4.1	58
20	Treatment Options for Hepatobiliary and Pancreatic Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 628-637.	3.0	58
21	EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 161-169.	1.0	58
22	Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 728-738.e9.	4.4	49
23	Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. <i>European Journal of Surgical Oncology</i> , 2018, 44, 677-683.	1.0	44
24	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	6.3	44
25	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. <i>Clinical Colorectal Cancer</i> , 2014, 13, 100-109.	2.3	41
26	Association Study of the let-7 miRNA-Complementary Site Variant in the 3' Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). <i>Clinical Cancer Research</i> , 2014, 20, 3319-3327.	7.0	40
27	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa023.	2.9	36
28	Treatment Advances in Liver-Limited Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 258-265.	2.3	34
29	Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 321-327.	1.2	34
30	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016, 21, 1509-1521.	3.7	33
31	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	1.6	32
32	N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 211-213.	2.3	29
33	Update on the optimal management of patients with colorectal liver metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 59-70.	4.4	29
34	A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). <i>Oncologist</i> , 2019, 24, 589-e160.	3.7	27
35	Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). <i>International Journal of Cancer</i> , 2019, 145, 380-389.	5.1	22
36	Gastric cancer in Alaska Native people: A cancer health disparity. <i>World Journal of Gastroenterology</i> , 2018, 24, 2722-2732.	3.3	18

#	ARTICLE	IF	CITATIONS
37	Molecular Classification of Gastric Cancer among Alaska Native People. <i>Cancers</i> , 2020, 12, 198.	3.7	18
38	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	2.8	18
39	Cancers of the Buccal Cavity and Pharynx in Circumpolar Inuit. <i>Acta OncolÃ³gica</i> , 1996, 35, 545-552.	1.8	17
40	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	5.1	16
41	Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 582-588.	1.4	15
42	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	2.8	15
43	Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973â€“2007. <i>International Journal of Circumpolar Health</i> , 2012, 71, 17521.	1.2	14
44	Impact of diabetes and metformin use on recurrence and outcome in stage IIâ€“III colon cancer patientsâ€™ A pooled analysis of three adjuvant trials. <i>European Journal of Cancer</i> , 2022, 166, 100-111.	2.8	13
45	Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials. <i>Clinical Cancer Research</i> , 2014, 20, 4176-4185.	7.0	12
46	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091091.	3.2	12
47	Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). <i>European Journal of Cancer</i> , 2021, 150, 214-223.	2.8	12
48	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 379-386.	0.3	11
49	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. <i>Oncologist</i> , 2020, 25, 380-e763.	3.7	10
50	Kidney and Bladder Cancer in Inuit 1969-1988. <i>Acta OncolÃ³gica</i> , 1996, 35, 595-599.	1.8	9
51	Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3525-3525.	1.6	9
52	Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 23-30.	2.3	8
53	Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 314-314.	1.6	8
54	Malignant Neoplasms of the Lymphatic and Haematopoietic System in Circumpolar Inuit. <i>Acta OncolÃ³gica</i> , 1996, 35, 601-606.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. <i>Transplant International</i> , 2015, 28, 1383-1391.	1.6	7
56	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1349-1358.	2.5	6
57	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. <i>European Journal of Cancer</i> , 2021, 159, 247-258.	2.8	6
58	Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11-11.	1.6	6
59	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
60	Updated Options for Liver-Limited Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, S58-S62.	2.3	4
61	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	3.0	4
62	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). <i>Investigational New Drugs</i> , 2021, 39, 1072-1080.	2.6	4
63	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab070.	2.9	4
64	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3520-3520.	1.6	4
65	Occurrence of esophageal and gastric cancer in Alaska Natives, 1969-2003. <i>Alaska Medicine</i> , 2006, 48, 2-11.	0.1	4
66	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	1.5	2
67	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	3.0	2
68	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	2
69	Use of neoadjuvant and postoperative chemotherapy with surgical resection of colorectal cancer hepatic metastases. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 100-105.	0.5	1
70	Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 110-115.	1.1	1
71	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 404-411.	2.5	1
72	Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 81-84.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Do we need biologic agents in preoperative systemic therapy of liver metastases?. Current Colorectal Cancer Reports, 2009, 5, 114-119.	0.5	0
74	Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?â€”Reply. JAMA Oncology, 2017, 3, 1285.	7.1	0
75	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.. Journal of Clinical Oncology, 2012, 30, 446-446.	1.6	0